New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

The “Before” and “After” photos are breaking the internet. Facebook groups, Reddit threads and gobs of other social media ...

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...

As the buzz around GLP-1 medications grew to a fever pitch over the past two years, many digital health and telehealth ...

Wegovy’s key competitor is Eli Lilly’s GLP-1 drug Mounjaro (tirzepatide), which became India’s top-selling medicine in ...

Among GLP-1 users, more than half said they will eat smaller portions and skip more treats this festive season ...

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

A USD 95 billion weight loss revolution is reshaping the global healthcare landscape, and India is emerging as one of its ...

The FDA announced six more awardees for the FDA Commissioner's National Priority Voucher (CNPV) pilot program designed to ...

Novo Nordisk has reduced the prices of Wegovy by 37%. The obesity pen's lowest dose of 0.25 mg will sell at Rs 10,850 for a ...

Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...